MERIDIAN
M&AHealthcareSIGNED

Eli Lilly Agrees to Acquire Calytrix Bio

Photo via Pexels
Acquirer
Eli Lilly
Target
Calytrix Bio

Eli Lilly has agreed to acquire Calytrix Bio for US$1.5 billion in a bet against blood cancer. The target has backing from JP Morgan private equity and Westlake BioPartners.

✦ Meridian Analysis
Eli Lilly has agreed to acquire Calytrix Bio for $1.5 billion, a 2025‑founded biotech backed by JPMorgan Life Sciences Private Capital and Westlake BioPartners. The transaction has been agreed, with Lilly agreeing to pay an undisclosed cash amount upfront and additional milestone payments that hinge on the achievement of specified clinical outcomes. Calytrix’s flagship asset is a laboratory‑produced protein designed to treat essential thrombocythemia and myelofibrosis, two rare blood cancers for which current therapies only manage symptoms. Key details still pending include the exact cash component, the milestone thresholds, the integration timetable, and the names of advisers or lenders involved. Observers will also watch for regulatory approvals and the timing of any subsequent funding rounds that may support Calytrix’s development pipeline under Lilly’s umbrella.
Read the original at Alertas PE Espana →2026-11-16North America
The Meridian Weekly

The week's largest deals and the Iberian ones, every Monday. Free.

MORE DEALS ON MERIDIAN ->